Sugi Predict

Sugi Predict / Compounds / SCHEMBL431291

SCHEMBL431291

SCHEMBL431291

Cc1c(-c2ccc(F)cc2)nc(N(C)S(C)(=O)=O)nc1C(C)C

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ HMGCR P04035 6/20 0.55
▸ ALDH1A1 P00352 1/20 0.55
▸ CYP3A4 P08684 1/20 0.55
▸ PDE6D O43924 1/20 0.55
▸ NR1I2 O75469 1/20 0.55
▸ PDE4D Q08499 1/20 0.55
▸ ABCC3 O15438 1/20 0.53
▸ ABCC4 O15439 1/20 0.53
▸ HDAC1 Q13547 1/20 0.52
▸ HDAC2 Q92769 1/20 0.52
▸ HDAC6 Q9UBN7 1/20 0.52
▸ AKT1 P31749 2/20 0.49
▸ GCGR P47871 1/20 0.40
▸ PTGS1 P23219 2/20 0.39
▸ PTGS2 P35354 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7913752 0.90 HMGCR (0.46) HMGCRALDH1A1CYP3A4PDE6DNR1I2
SCHEMBL6804623 0.87 HMGCR (0.55) HMGCRALDH1A1CYP3A4PDE6DNR1I2
SCHEMBL16429688 0.87 HMGCR (0.43) HMGCRALDH1A1CYP3A4PDE6DNR1I2
SCHEMBL2341001 0.86 HMGCR (0.54) HMGCRALDH1A1CYP3A4PDE6DNR1I2
SCHEMBL4620964 0.86 HMGCR (0.54) HMGCRALDH1A1CYP3A4PDE6DNR1I2
SCHEMBL2347371 0.86 HMGCR (0.54) HMGCRALDH1A1CYP3A4PDE6DNR1I2
SCHEMBL14403869 0.86 HMGCR (0.56) HMGCRALDH1A1CYP3A4PDE6DNR1I2
SCHEMBL2339006 0.86 HMGCR (0.54) HMGCRALDH1A1CYP3A4PDE6DNR1I2
SCHEMBL13538 0.85 HMGCR (0.61) HMGCRALDH1A1CYP3A4PDE6DNR1I2
SCHEMBL3445256 0.85 HMGCR (0.56) HMGCRALDH1A1CYP3A4PDE6DNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115521260-B Synthesis method of rosuvastatin tert-butyl ester 江苏阿尔法药业股份有限公司 2025-02-11 — — CN disclosed
CN-115521260-A Synthetic method of rosuvastatin calcium tert-butyl ester 江苏阿尔法药业股份有限公司 2022-12-27 — — CN disclosed
US-11344548-B2 Analogs of 3,5-dihydroxypentanoate for bone formation KAOHSIUNG MEDICAL UNIVERSITY (TW) 2022-05-31 — — US disclosed
US-20210322411-A1 ANALOGS OF 3,5-DIHYDROXYPENTANOATE FOR BONE FORMATION KAOHSIUNG MEDICAL UNIVERSITY (TW) 2021-10-21 — — US disclosed
EP-2247739-B1 ((2S,4R)-4,6-DIHYDROXYTETRAHYDRO-2H-PYRAN-2-YL)METHYL CARBOXYLATE AND PROCESS FOR ITS PRODUCTION EMPLOYING A 2-DEOXYRIBOSE-5-PHOSPHATE ALDOLASE (DERA) LEK PHARMACEUTICALS (SI) 2018-05-16 — — EP disclosed
US-9932361-B2 Convenient process for the preparation of statins F.I.S. - FABBRICA ITALIANA SINTETICI S.P.A. (IT) 2018-04-03 — — US disclosed
EP-2655650-B1 ENZYMATIC SYNTHESIS OF ACTIVE PHARMACEUTICAL INGREDIENT AND INTERMEDIATES THEREOF LEK PHARMACEUTICALS (SI) 2017-12-20 — — EP disclosed
US-9676729-B2 Amine salts of pitavastatin and rosuvastatin DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) 2017-06-13 — — US disclosed
US-9676729-B2 Amine salts of pitavastatin and rosuvastatin DSM SINOCHEM PHARMACEUTICALS NETHERLANDS B.V. (NL) 2017-06-13 — — US disclosed
EP-2134696-B1 PROCESSES FOR THE PREPARATION OF STATINS, PARTICULARLY ROSUVASTATIN, AND INTERMEDIATES FOR THE PREPARATION THEREOF LEK PHARMACEUTICALS (SI) 2017-05-17 — — EP disclosed
WO-2007125547-A2 NOVEL PROCESS FOR STATINS AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF SATYANARAYANA REDDY MANNE (IN) 2007-11-08 — — WO disclosed
EP-1825848-A2 Stable pharmaceutical compositions comprising an HMG-CoA reductase inhibitor STADA ARZNEIMITTEL AG (DE) 2007-08-29 — — EP disclosed
EP-1818050-A1 Stable pharmaceutical compositions comprising a HMG-CoA reductase inhibitor STADA ARZNEIMITTEL AG (DE) 2007-08-15 — — EP disclosed
US-20070161699-A1 Method of preventing or treating glaucoma DUKE UNIVERSITY (US) 2007-07-12 — — US disclosed
US-20070161699-A1 Method of preventing or treating glaucoma DUKE UNIVERSITY (US) 2007-07-12 — — US disclosed
EP-1775299-A1 Process for the synthesis of HMG-CoA reductase inhibitors LEK Pharmaceuticals D.D. (SI) 2007-04-18 — — EP disclosed
WO-2007039287-A1 PROCESS FOR THE SYNTHESIS OF HMG-CoA REDUCTASE INHIBITORS LEK PHARMACEUTICALS D.D. (SI) 2007-04-12 — — WO disclosed
WO-2007007119-A1 PROCESSES FOR THE MANUFACTURE OF ROSUVASTATIN AND INTERMEDIATES ASTRAZENECA UK LIMITED (GB) 2007-01-18 — — WO disclosed
WO-2006067456-A2 PROCESS FOR PREPARING ROSUVASTATIN ASTRAZENECA UK LIMITED (GB) 2006-06-29 — — WO disclosed
WO-2005105069-A1 STATINS FOR THE TREATMENT OF OCULAR HYPERTENSION AND GLAUCOMA ALCON, INC. (CH) 2005-11-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11344548-B2 Analogs of 3,5-dihydroxypentanoate for bone formation CYP24A1, CYP27B1, CYP2R1 HMGCR 43/4885ALDH1A1 1047/4885CYP3A4 1304/4885
US-20210322411-A1 ANALOGS OF 3,5-DIHYDROXYPENTANOATE FOR BONE FORMATION CYP24A1, CYP27B1, CYP2R1 HMGCR 43/4885ALDH1A1 1047/4885CYP3A4 1304/4885
US-20070161699-A1 Method of preventing or treating glaucoma HMGCR, RHOA, PDE3A HMGCR 1/4885ALDH1A1 1641/4885CYP3A4 2361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.